Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiolabeled BIA 5-1058 ADME and mass balance study in healthy men
NL-OMON45578Active, not recruiting
- Sponsor
- BIAL
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of zamicastat in heart failure (HF), pulmonary hypertension (PH) and cardiac morbidity, sponsored by BIAL. Primary endpoints: Excretion routes and mass balance, Pharmacokinetics of total radioactivity and 1 more. Started Mar 2017; status: active, not recruiting.
02
Drugs
zamicastat
03
Conditions
heart failure (HF)pulmonary hypertension (PH)cardiac morbidity
Beyond the preview
Go deeper on NL-OMON45578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45578.